Michael Burkes Brophy Sells 43,502 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 43,502 shares of Natera stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the sale, the chief financial officer now directly owns 70,629 shares in the company, valued at $12,492,857.52. The trade was a 38.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Trading Up 1.6 %

NASDAQ:NTRA opened at $177.00 on Thursday. The company has a 50 day simple moving average of $167.43 and a two-hundred day simple moving average of $139.78. The company has a market cap of $23.37 billion, a PE ratio of -100.57 and a beta of 1.66. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $67.33 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.95) earnings per share. Research analysts forecast that Natera, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its position in Natera by 24.5% in the second quarter. The Manufacturers Life Insurance Company now owns 36,257 shares of the medical research company’s stock worth $3,926,000 after acquiring an additional 7,132 shares during the period. Mackenzie Financial Corp bought a new position in Natera in the 2nd quarter worth $317,000. Creative Planning grew its holdings in Natera by 28.3% during the second quarter. Creative Planning now owns 4,929 shares of the medical research company’s stock valued at $534,000 after purchasing an additional 1,087 shares during the period. Quarry LP increased its position in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Natera in the second quarter worth about $380,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NTRA. JPMorgan Chase & Co. upped their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Craig Hallum upped their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. TD Cowen increased their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Robert W. Baird lifted their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.